Peptide ReadinessJoin the beta
Back to database

FDA 2027 COMPOUNDING REVIEW

GHK-Cu

Cosmetic familiarity can create false reassurance when route, formulation or claims move into medicinal territory.

Record version 1.0Last verified 5 September 2026Evidence grade DRegulatory surveillance cohort
FDA STATUS

Not FDA approved as an injectable wellness medicine; committee consideration is not approval

MHRA / UK LICENCE

No UK injectable marketing authorisation identified for wellness use

NICE STATUS

No NICE recommendation identified for injectable wellness use

NHS ACCESS

No routine NHS access for this use

PRIVATE LAWFUL USE CONTEXT

Cosmetic use and medicinal injection are legally distinct

EVIDENCE MATURITY

Cosmetic and biological literature does not validate injectable blend claims

DEVELOPMENT PHASE

Regulatory surveillance cohort

MARKET EXPOSURE

Very high

PROFESSIONAL RELEVANCE

Separate cosmetic use, medicinal presentation and research market injection claims.

Product, formulation and indication

No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.

Status history

Production baseline verification recorded.

Listed for forthcoming FDA PCAC consideration

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.